← Back to Analyst Consensus 
TARA Buy
Protara Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 14
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Oct 29, 2026 (3 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| May 20, 2026 | Oppenheimer | maintain | Outperform → Outperform | $28 | 52% |
| May 14, 2026 | JP Morgan | maintain | Overweight → Overweight | $26 | 55% |
| Apr 29, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $27 | 44% |
| Mar 4, 2026 | JP Morgan | initiate | — → Overweight | — | 55% |
| Feb 10, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $23 | 44% |
| Jan 7, 2026 | Piper Sandler | initiate | — → Overweight | $24 | 54% |
| Dec 3, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $23 | 44% |
| Nov 19, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $23 | 44% |
| May 22, 2025 | Jones Trading | initiate | — → Buy | $21 | 50% |
| Apr 28, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $23 | 44% |
| Apr 16, 2025 | Scotiabank | initiate | — → Sector Outperform | $12 | 55% |
| Mar 14, 2025 | Cantor Fitzgerald | initiate | — → Overweight | $0 | 50% |
| Mar 11, 2025 | LifeSci Capital | initiate | — → Outperform | $22 | 57% |
| Mar 6, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $23 | 44% |
| Dec 6, 2024 | Guggenheim | reiterate | Buy → Buy | $20 | 52% |
| Dec 6, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $23 | 44% |
| Nov 14, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $23 | 44% |
| Aug 12, 2024 | Oppenheimer | maintain | Outperform → Outperform | $25 | 52% |
| Aug 8, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $23 | 44% |
| May 6, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $23 | 44% |
| Apr 22, 2024 | Oppenheimer | maintain | Outperform → Outperform | $30 | 52% |
| Apr 8, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $23 | 44% |
| Mar 14, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $23 | 44% |
| Aug 4, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $23 | 44% |
| May 8, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $23 | 44% |
| May 1, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $23 | 44% |
| Mar 9, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $23 | 44% |
| Aug 10, 2022 | HC Wainwright & Co. | maintain | — → Buy | $23 | 44% |
| May 9, 2022 | HC Wainwright & Co. | maintain | — → Buy | $30 | 44% |
| Nov 8, 2021 | Oppenheimer | maintain | — → Outperform | $34 | 52% |
| Jun 4, 2021 | HC Wainwright & Co. | initiate | — → Buy | $40 | 44% |
| Oct 19, 2020 | Cowen & Co. | initiate | — → Outperform | $50 | — |
| Jul 29, 2020 | Guggenheim | initiate | — → Buy | $50 | 52% |
Price Target Trend
May 12, 2026 Oct 26, 2026
EPS Estimates
0y —
+1y —
0q —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days